Ex­clu­sive: Pic­tion Health rais­es $6M to cut wait times for skin con­di­tions

Last year
Financing
Health Tech

Neu­ro­crine wins ap­proval of In­grez­za 'sprin­kle' for­mu­la­tion for pa­tients with trou­ble swal­low­ing

Last year
Pharma
FDA+

FTC tar­gets more drug patents, go­ing af­ter obe­si­ty, di­a­betes and asth­ma med­ica­tions

Last year
Pharma
FDA+

FDA asks for pub­lic in­put on ad­vi­so­ry com­mit­tee re­forms

Last year
Pharma
FDA+

Mar­ket­ingRx roundup: Mod­er­na de­buts so­cial me­dia sci­ence se­ries; Boehringer ex­pands NY men­tal health ex­hib­it

Last year
Pharma
Marketing

Unit­ed­Health CEO re­veals cy­ber­at­tack ori­gins ahead of Change Health­care hear­ings

Last year
FDA+
Health Tech

Daré's roy­al­ty deal; Qlaris Bio rais­es $24M

Last year
News Briefing

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

Last year
R&D
Pharma

Re­al Chem­istry de­buts a one-stop dash­board for all things GLP-1

Last year
Pharma
Marketing

Har­mo­ny Bio­sciences buys small epilep­sy biotech for $35M, plus mile­stones

Last year
Deals

Wal­mart ex­its live and vir­tu­al care busi­ness, five years af­ter push in­to care de­liv­ery

Last year
Health Tech

Up­dat­ed: Lil­ly boosts sales guid­ance by $2B, but GLP-1 sup­ply con­straints still a fo­cus

Last year
Pharma
Manufacturing

In one of JP Mor­gan's first biotech bets, En­laza rais­es $100M for its per­ma­nent­ly bind­ing pro­tein drugs

Last year
Financing

No­var­tis hands Pep­tiDream $180M up­front to ex­tend ra­dio­phar­ma dis­cov­ery pact

Last year
Deals
R&D

DNA se­quenc­ing firm PacBio to lay off work­ers and shut­ter San Diego of­fice

Last year
Diagnostics

Fed­er­al judge throws out two drug­mak­er IRA law­suits in win for gov­ern­ment

Last year
Pharma
Law

FDA con­verts Pfiz­er's Tiv­dak to full ap­proval in cer­vi­cal can­cer

Last year
Pharma
FDA+

FDA fi­nal­izes long-await­ed rule to bring lab tests un­der its purview

Last year
Pharma
FDA+

No­vo Nordisk's once-week­ly in­sulin will face FDA ad­comm in May, fol­low­ing re­view ex­ten­sion

Last year
Pharma
FDA+

Mer­ck touts up­dat­ed 21-va­lent pneu­mo­coc­cal da­ta weeks ahead of FDA de­ci­sion: Cor­rect­ed

Last year
R&D

Phar­ma rep­u­ta­tion slips among pa­tient ad­vo­ca­cy groups, ac­cord­ing to an­nu­al sur­vey

Last year
Pharma
Marketing

Sanofi and Re­gen­eron de­but next gen­er­a­tion in Dupix­en­t's asth­ma cam­paign

Last year
Pharma
Marketing

Prime Med­i­cine re­ceives FDA clear­ance to run first prime edit­ing clin­i­cal tri­al

Last year
R&D
Cell/Gene Tx

WuXi wants to re­gain client con­fi­dence amid claims of IP trans­fer to Chi­nese au­thor­i­ties 

Last year
China
Manufacturing
First page Previous page 164165166167168169170 Next page Last page
A service from the Financial Times